AR119625A1 - Inhibidores de jak - Google Patents
Inhibidores de jakInfo
- Publication number
- AR119625A1 AR119625A1 ARP200102264A ARP200102264A AR119625A1 AR 119625 A1 AR119625 A1 AR 119625A1 AR P200102264 A ARP200102264 A AR P200102264A AR P200102264 A ARP200102264 A AR P200102264A AR 119625 A1 AR119625 A1 AR 119625A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- hydrogen
- independently selected
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1); donde: el anillo A es fenilo o un anillo heteroarilo C₂₋₉; el anillo B es un anillo heterocicloalquilo C₂₋₉; X es C(R¹¹) o N; L¹ es alquilo C₁₋₆ o heteroalquilo C₁₋₆; L² es un enlace o alquilo C₁₋₆; R¹ es alquilo C₃₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆ o heteroarilo C₂₋₉, donde el alquilo C₃₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆ o heteroarilo C₂₋₉ se sustituye opcionalmente con 1, 2 ó 3 R⁵; cada R³ se selecciona de forma independiente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, heteroalquilo C₁₋₆, -OR⁷, -N(R⁷)₂, -CN, -C(=O)R⁸, -C(=O)OR⁷, -C(=O)N(R⁷)₂, -NR⁷C(=O)R⁸, -NR⁷S(=O)₂R⁸, -S(=O)₂R⁸ y -S(=O)₂N(R⁷)₂; R⁴ es hidrógeno, alquilo C₁₋₆ o heteroalquilo C₁₋₆; cada R⁵ se selecciona de forma independiente de halógeno, oxo, alquilo C₁₋₆, haloalquilo C₁₋₆, heteroalquilo C₁₋₆, -OR⁷, -N(R⁷)₂, -CN, -C(=O)R⁸, -C(=O)OR⁷, -C(=O)N(R⁷)₂, -NR⁷C(=O)R⁸, -NR⁷S(=O)₂R⁸, -S(=O)₂R⁸ y -S(=O)₂N(R⁷)₂; cada R⁷ se selecciona de forma independiente de hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, haloalquilo C₁₋₆ y heteroalquilo C₁₋₆; cada R⁸ se selecciona de forma independiente de alquilo C₁₋₆, alquenilo C₂₋₆, heteroalquilo C₁₋₆, cicloalquilo C₃₋₆ y heterocicloalquilo C₂₋₉; R¹¹ es hidrógeno o alquilo C₁₋₆ que se sustituye opcionalmente con 1, 2 ó 3 R⁵; R¹² es hidrógeno, halógeno o alquilo C₁₋₆; R¹³ se selecciona de hidrógeno y alquilo C₁₋₆; cada R¹⁴ se selecciona de forma independiente de alquilo C₁₋₆, haloalquilo C₁₋₆, heteroalquilo C₁₋₆; -OR⁷, -N(R⁷)₂ y oxo; n es 0, 1, 2 ó 3; y p es 0, 1, 2 ó 3; o una sal o solvato farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962884593P | 2019-08-08 | 2019-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119625A1 true AR119625A1 (es) | 2021-12-29 |
Family
ID=74499223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102264A AR119625A1 (es) | 2019-08-08 | 2020-08-07 | Inhibidores de jak |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11459333B2 (es) |
| EP (1) | EP4009967A4 (es) |
| JP (1) | JP2022544174A (es) |
| KR (1) | KR20220051351A (es) |
| CN (1) | CN115038436A (es) |
| AR (1) | AR119625A1 (es) |
| AU (1) | AU2020325152A1 (es) |
| BR (1) | BR112022002390A2 (es) |
| CA (1) | CA3150281A1 (es) |
| IL (1) | IL290381A (es) |
| MX (1) | MX2022001702A (es) |
| TW (1) | TW202122400A (es) |
| WO (1) | WO2021026465A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021013602A (es) | 2019-05-08 | 2022-04-06 | Vimalan Biosciences Inc | Inhibidores de jak. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008117151A (ru) | 2005-09-30 | 2009-11-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины, пригодные в качестве ингибиторов янус-киназ |
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| WO2008094602A2 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases |
| EP2247591A1 (en) * | 2008-02-06 | 2010-11-10 | Novartis AG | Pyrrolo [2, 3-d]pyridines and use thereof as tyrosine kinase inhibitors |
| BR112012009327A2 (pt) * | 2009-10-20 | 2017-06-06 | Cellzome Ltd | análogos de heterociclil pirazolopirimidina como inibidores de jak |
| CA2797772A1 (en) * | 2010-04-30 | 2011-11-03 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
| WO2012143320A1 (en) * | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| BR112014032913A2 (pt) | 2012-06-29 | 2017-06-27 | Pfizer | novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2 |
| BR112017027951A2 (pt) | 2015-06-22 | 2018-08-28 | Ono Pharmaceutical Co., Ltd. | composto inibitório de brk |
| MX2021013602A (es) | 2019-05-08 | 2022-04-06 | Vimalan Biosciences Inc | Inhibidores de jak. |
-
2020
- 2020-08-07 TW TW109126962A patent/TW202122400A/zh unknown
- 2020-08-07 CA CA3150281A patent/CA3150281A1/en active Pending
- 2020-08-07 AR ARP200102264A patent/AR119625A1/es unknown
- 2020-08-07 AU AU2020325152A patent/AU2020325152A1/en not_active Abandoned
- 2020-08-07 BR BR112022002390A patent/BR112022002390A2/pt unknown
- 2020-08-07 MX MX2022001702A patent/MX2022001702A/es unknown
- 2020-08-07 KR KR1020227007324A patent/KR20220051351A/ko active Pending
- 2020-08-07 CN CN202080070664.9A patent/CN115038436A/zh active Pending
- 2020-08-07 JP JP2022507741A patent/JP2022544174A/ja active Pending
- 2020-08-07 EP EP20850079.3A patent/EP4009967A4/en not_active Withdrawn
- 2020-08-07 WO PCT/US2020/045431 patent/WO2021026465A1/en unknown
- 2020-08-07 US US16/988,253 patent/US11459333B2/en active Active
-
2022
- 2022-02-06 IL IL290381A patent/IL290381A/en unknown
-
2023
- 2023-04-13 US US18/300,279 patent/US20230312589A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022001702A (es) | 2022-04-20 |
| TW202122400A (zh) | 2021-06-16 |
| BR112022002390A2 (pt) | 2022-06-14 |
| AU2020325152A1 (en) | 2022-03-10 |
| US20210040100A1 (en) | 2021-02-11 |
| EP4009967A4 (en) | 2023-07-26 |
| KR20220051351A (ko) | 2022-04-26 |
| CA3150281A1 (en) | 2021-02-11 |
| EP4009967A1 (en) | 2022-06-15 |
| JP2022544174A (ja) | 2022-10-17 |
| WO2021026465A1 (en) | 2021-02-11 |
| US11459333B2 (en) | 2022-10-04 |
| US20230312589A1 (en) | 2023-10-05 |
| IL290381A (en) | 2022-04-01 |
| CN115038436A (zh) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| AR113765A1 (es) | Inhibidores de la proteasa del vih | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR118837A1 (es) | Moduladores de la vía integrada del estrés | |
| AR110405A1 (es) | Compuestos | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR102731A1 (es) | Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor | |
| AR111756A1 (es) | 4-difluorometilbenzoilamidas de acción herbicida | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095721A1 (es) | Derivados de piridina | |
| AR089959A1 (es) | Compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
| AR119625A1 (es) | Inhibidores de jak | |
| AR093128A1 (es) | Inhibidores de la syk | |
| AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |